 Home > Active Ingredient News > Antitumor Therapy > JNCI: The best endocrine choice after adjuvant chemotherapy for perimenopausal breast cancer patients

JNCI: The best endocrine choice after adjuvant chemotherapy for perimenopausal breast cancer patients

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

etiology cancer

1 4 fitting

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

We know that for patients with early-stage estrogen receptor-positive (ER+) breast cancer , endocrine therapy after postoperative adjuvant chemotherapy can benefit patients
.

For premenopausal and postmenopausal patients, the efficacy of adjuvant aromatase inhibitor (AI) versus tamoxifen has been proven in randomized clinical studies

We know that for patients with early-stage estrogen receptor-positive (ER+) breast cancer , endocrine therapy after postoperative adjuvant chemotherapy can benefit patients

The study included ER+ breast cancer patients with T 1-4 N any M 0 in women aged 45-50 who were diagnosed in the Netherlands from 2004 to 2007
.

Calculate the ratio of AI treatment time/total endocrine treatment time

The study included ER+ breast cancer patients with T 1-4 N any M 0 in women aged 45-50 who were diagnosed in the Netherlands from 2004 to 2007

A total of 2295 patients were enrolled in the study.

The average follow-up time was 7.

Different groups of RFS

Similarly, compared with patients with AI<25%, patients with AI>75% had longer OS, and the 5-year OS rates were 97.
3% (95% CI = 96.
4%-98.
4%) and 94.
6% (95%CI = 93.
6%-96.
1) %) (adjusted HR = 0.
50, 95% CI = 0.
34-0.
74); 5-year OS rates for AI 25%-75% and AI<25% patients were 97.
6% (95% CI = 97.
0%-98.
4%) And 94.
6% (95% CI = 93.
6%-96.
1%)
.

Trend analysis found that every 10% increase in AI treatment time can reduce the risk of OS by 10% (p<0.

Similarly, compared with patients with AI<25%, patients with AI>75% had longer OS, and the 5-year OS rates were 97.

Different groups of OS

In summary, the study shows that for patients with ER+ breast cancer aged 45-50 years, the best endocrine therapy after postoperative adjuvant chemotherapy is therapy that contains aromatase inhibitors (AI)
.

The study showed that for patients with ER+ breast cancer aged 45-50 years, the best endocrine therapy after adjuvant chemotherapy after surgery is treatment containing aromatase inhibitors (AI)

Original source:

Gwen MHE Dackus, Katarzyna Jóźwiak, Gabe S Sonke, et al.

Gwen MHE Dackus, Katarzyna Jóźwiak, Gabe S Sonke, et al.
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
J Natl Cancer Inst.
2021 Jun 8;djab091.
doi: 10.
1093/jnci ahead of print .
in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.